| Heading: |
Methylphenidate and Pancreatic Enzyme Replacement Therapy |
| Question ID: |
1792319 |
| UIN: |
44145 |
| House: |
Commons |
| Date tabled: |
2025-04-03 |
| Asking Member ID: |
5335 |
| Asking Member display name: |
Jess Brown-Fuller
|
| Asking Member handle: |
JessBrownFuller
|
| Asking Member Twitter reference: |
@JessBrownFuller
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what progress he has made on increasing the availability of (a) methylphenidate and (b) pancreatic enzyme replacement therapy. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-09 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
As a result of intensive work, some issues with attention deficit hyperactivity disorder medicines have resolved. All strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, and guanfacine prolonged-release tablets are now availabl... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |